Home/Filings/4/0001209191-19-053922
4//SEC Filing

Lavelle Erin 4

Accession 0001209191-19-053922

CIK 0001423824other

Filed

Oct 23, 8:00 PM ET

Accepted

Oct 24, 7:12 PM ET

Size

14.3 KB

Accession

0001209191-19-053922

Insider Transaction Report

Form 4
Period: 2019-10-22
Lavelle Erin
Chief Commercial Officer
Transactions
  • Award

    Common Stock

    2019-10-22+11,68416,092 total
  • Disposition from Tender

    Common Stock

    2019-10-22$18.00/sh16,092$289,6560 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-10-22150,0000 total
    Exercise: $14.00Exp: 2029-02-05Common Stock (150,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2019-10-22300,0000 total
    Exercise: $14.55Exp: 2028-04-15Common Stock (300,000 underlying)
Footnotes (7)
  • [F1]On August 13, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 17,526 shares of Issuer's Common Stock ("RSU"), of which 5,842 shares had vested and the remaining 11,684 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 4).
  • [F2]On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer.
  • [F3]The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.
  • [F4]On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.
  • [F5]The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of April 16, 2018 (the "2018 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date.
  • [F6]The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.
  • [F7]The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the "2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date.

Issuer

ALDER BIOPHARMACEUTICALS INC

CIK 0001423824

Entity typeother

Related Parties

1
  • filerCIK 0001737613

Filing Metadata

Form type
4
Filed
Oct 23, 8:00 PM ET
Accepted
Oct 24, 7:12 PM ET
Size
14.3 KB